Design, synthesis, and antihepatitis B virus activities of novel 2-pyridone derivatives

Journal of Medicinal Chemistry

Volumn 53, Issue 2, 2010, Pages 660-668

  Lv, Zhiliang ^a   Sheng, Chunquan ^a   Wang, Tiantian ^a   Zhang, Yikai ^a   Liu, Jia ^a   Feng, Jilu ^a   Sun, Hailing ^a   Zhong, Hanyu ^a   Niu, Chunjuan ^a   Li, Ke ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 ETHOXYPHENYL) 5 (2 HYDROXY 4 METHOXYBENZOYL)PYRIDIN 2(1H) ONE; 1 BUTYL 5 [(BUTYLIMINO)(2 HYDROXY 4 METHOXYPHENYL)METHYL]PYRIDIN 2(1H) ONE; 2 PYRIDONE DERIVATIVE; 5 (2 HYDROXY 4 METHOXYBENZOYL) 1 PHENYLPYRIDIN 2(1H) ONE; ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; CLEVUDINE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DNA REPLICATION; DRUG SELECTIVITY; DRUG SYNTHESIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; HYDROPHOBICITY; NONHUMAN; PHARMACOPHORE; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; VIRUS HEPATITIS; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE; DNA REPLICATION; DRUG DESIGN; HEPATITIS B VIRUS; HUMANS; MODELS, MOLECULAR; PYRIDONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77249122549     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901237x     Document Type: Article

References (21)

1. Lavanchy, D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepatitus 2004, 11, 97-107.
2. Dienstag, J. L. Hepatitis B virus infection. N. Engl. J. Med. 2009, 359, 1486-1500.
3. Sorrell, M. F.; Belongia, E. A.; Costa, J.; Gareen, I. F.; Grem, J. L.; Inadomi, J. M.; Kern, E. R.; McHugh, J. A.; Petersen,G. M.; Rein, M. F.; Strader, D. B.; Trotter, H. T. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis B. Ann. Intern. Med. 2009, 150, 104-110.
4. Liang, T. J. Hepatitis B: the virus and disease. Hepatology 2009, 49 (S5), S13-S21.
5. Lui, Y. Y.; Chan, H. L. Treatment of chronic hepatitis B: focus on telbivudine. Expert Rev. Anti-Infect. Ther. 2009, 7, 259-268.
6. Cheng, P. N.; Chang, T. T. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients. Expert Rev. Anti-Infect. Ther. 2008, 6, 569-579.
7. Shamliyan, T. A.; MacDonald, R.; Shaukat, A.; Taylor, B. C.; Yuan, J.-M.; Johnson, J. R.; Tacklind, J.; Rutks, I.; Kane, R. L.; Wilt, T. J. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann. Intern. Med. 2009, 150, 111-125.
8. Wong, D. K.; Cheung, A. M.; O'Rourke, K.; Naylor, C. D.; Detsky, A. S.; Heathcote, J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B.A meta-analysis. Ann. Intern. Med. 1993, 119, 312-23.
9. Perrillo, R. P.; Schiff, E. R.; Davis, G. L.; Bodenheimer, H. C., Jr.; Lindsay, K.; Payne, J.; Dienstag, J. L.; O'Brien, C.; Tamburro, C.; Jacobson, I. M.; et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1990, 323, 295-301.
10. Nevens, F.; Main, J.; Honkoop, P.; Tyrrell, D. L.; Barber, J.; Sullivan, M. T.; Fevery, J.; De Man, R. A.; Thomas, H. C. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997, 113, 1258-1263.
11. Dusheiko, G.; Bertoletti, A. Resistance to lamivudine therapy: is there more than meets the eye? Gut 2005, 54, 9-10.
12. Malik, A. H.; Lee, W. M. Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann. Intern. Med. 2000, 132, 723-31.
13. Hepsera Full Prescribing Information; Gilead Sciences: Foster City, CA, September 2002; pp 1-18.
14. Dong, H.-W.; Li, K.; Zheng, C.-H; Liu, J.; Lv, Z.-L.; Li, T.-J.; Liu, C.-M. Synthesis and antitumor activity of novel 3-(substituted amino)-chromone derivatives. Acta Chim. Sin. 2009, 67, 819-824.
15. Corbet, J.-P.; Mignani, G. Selected patented cross-coupling reaction technologies. Chem. Rev. 2006, 106, 2651-2710.
16. Yin, L.; Liebscher, J. Carbon-carbon coupling reactions catalyzed by heterogeneous palladium catalysts. Chem. Rev. 2007, 107, 133-173.
17. Jones, G.; Willett, P.; Glen, R. C. A genetic algorithm for flexible molecular overlay and pharmacophore elucidation. J. Comput.-Aided Mol. Des. 1995, 9, 532-549.
18. T. Mosmann, J. I. Methods 1983, 65, 55-63.
19. Li, Y.-F.; Wang, G.-F.; Luo, Y.; Huang, W.-G.; Tang, W.; Feng, C.-L.; Shi, L.-P.; Ren, Y.-D.; Zuo, J.-P.; Lu, W. Identification of 1-isopropylsulfonyl-2-amine benzimidazoles as a new class of inhibitors of hepatitis B virus. Eur. J. Med. Chem. 2007, 42, 1358-1364.
20. Li, Y.-F.; Wang, G.-F.; He, P.-L.; Huang, W.-G.; Zhu, F.-H.; Gao, H.-Y.; Tang, W.; Luo, Y.; Feng, C.-L.; Shi, L.-P.; Ren, Y.-D.; Lu, W.; Zuo, J.-P. Synthesis and anti-hepatitis B virus activity of novel benzimidazole derivatives. J. Med. Chem. 2006, 49, 4790-4794.
21. SYBYL, version 6.9; Tripos Associates (Suite 303, St. Louis, MO 63144), 2003.